fashion -WSS

fashion

author：focus 2025-10-01 23:57:16 - browse：27153

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： ALS groups 'won't be played again' by the FDA, drug sponsors

hotspot

WSS

FDA authorizes Novavax’s updated Covid

Colorectal cancer study finds potential in overlooked immune cell

When women are denied an abortion, their children fare worse than peers

Was Amgen transparent enough on FDA's concern on cancer drug?

FDA authorizes Novavax’s updated Covid

A Q&A with the global head of Boehringer Ingelheim's innovation unit

focus

fashion

Wikipedia

Psychedelics group wrestles with new pharma identity

How to address the problem of discarded donor organs

Wildfire smoke exposes gaps in outdoor worker protections

What to expect at HLTH 2023, the health care industry conference

Sports medicine is finally prioritizing gender equality

Stroke deaths set to near 10 million globally by 2050

Moonlake's readout produced a cash windfall. Risks remain

RSV vaccines may be linked to small increased risk of developing GBS

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Wikipedia

How to address the problem of discarded donor organs

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

International team creates first chimeric human

Chan Zuckerberg Biohub Chicago to focus on inflammation

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Stroke deaths set to near 10 million globally by 2050

knowledge

hotspot

knowledge

hotspot